Neuropsychiatric Disease and Treatment
metrics 2024
Exploring the Frontiers of Neuropsychiatric Science
Introduction
Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.
Metrics 2024
Metrics History
Rank 2024
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
Progress in Neurology and Psychiatry
Illuminating the complexities of neurological and psychiatric disorders.Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.
Applied Neuropsychology-Adult
Innovating insights for adult psychological health.Applied Neuropsychology-Adult is a premier journal published by Routledge Journals, Taylor & Francis Ltd, dedicated to advancing the field of neuropsychology with a particular focus on adult populations. Since its inception in 2012, this journal has been a vital platform for disseminating innovative research, reviews, and clinical insights into the cognitive and psychological processes that influence adult behavior and functioning. With an impressive Scopus ranking, including Q3 status in both Developmental and Educational Psychology and Neuropsychology and Physiological Psychology, it demonstrates a commitment to high-quality scholarship that informs both clinical practice and theoretical understanding. Researchers, clinicians, and students alike will benefit from the journal's commitment to open access, providing broad access to valuable knowledge in the domain of neuropsychology. As it converges towards its 2024 milestone, Applied Neuropsychology-Adult continues to be an essential resource for those seeking to deepen their understanding of neuropsychological processes and their application in real-world settings.
PEDIATRIC NEUROLOGY
Empowering Healthcare through Cutting-edge Neurological StudiesPediatric Neurology, a prestigious journal published by Elsevier Science Inc, is a leading resource in the field of child neurology and developmental neurosciences. With an impressive impact factor and categorization in the Q1 and Q2 quartiles across several relevant fields, including Pediatrics, Neurology, and Developmental Neuroscience, this journal is essential for researchers and healthcare professionals focused on pediatric neurological disorders. Since its inception in 1985, it has provided a platform for high-quality research, clinical studies, and reviews that drive advancements in diagnosis, treatment, and understanding of neurological conditions in children. Although the journal does not currently offer open access, it maintains a robust reputation in the academic community, bolstered by its prominent ranking in Scopus metrics. By engaging with the latest findings published in Pediatric Neurology, readers will gain vital insights that contribute to improving pediatric healthcare outcomes in neurology and neuroscience.
CURRENT OPINION IN NEUROLOGY
Empowering Researchers with Current Neurological Perspectives.CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.
Neurology and Therapy
Empowering Practitioners with the Latest in Neurology and TherapyNeurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.
MOLECULAR PSYCHIATRY
Innovating Therapeutic Approaches through Molecular InsightsMOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.
Current Neuropharmacology
Innovating solutions for neurological challenges.Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.
NEUROPHARMACOLOGY
Advancing Knowledge at the Intersection of Neuroscience and PharmacologyNEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.
PSYCHIATRY AND CLINICAL NEUROSCIENCES
Innovating Research for Better Mental Health OutcomesPSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.
Journal of the Korean Academy of Child and Adolescent Psychiatry
Elevating discourse on child and adolescent psychiatry.The Journal of the Korean Academy of Child and Adolescent Psychiatry (ISSN: 1225-729X; E-ISSN: 2233-9183) stands as a pivotal resource in the fields of child and adolescent mental health, contributing significantly to the dialogue on psychiatric practices and research in South Korea and beyond. Published by the KOREAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY, this journal is recognized for its dedication to advancing the understanding of psychiatric disorders that affect children and adolescents, as evidenced by its Q3 ranking in both Pediatrics, Perinatology and Child Health and Psychiatry and Mental Health categories for 2023. Operated from Seoul, South Korea, the journal facilitates knowledge-sharing among researchers and practitioners, providing insights into clinical practices and innovative treatment methodologies. Although not openly accessible, the journal emphasizes quality over quantity in its selection of studies, making each article a valuable contribution to the field. As the journal continues to publish impactful research through 2024, it remains essential reading for those committed to the well-being of younger populations and their families.